<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34092044</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>18</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2328-9503</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>8</Volume>
            <Issue>7</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>Annals of clinical and translational neurology</Title>
          <ISOAbbreviation>Ann Clin Transl Neurol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Zonisamide-responsive myoclonus in SEMA6B-associated progressive myoclonic epilepsy.</ArticleTitle>
        <Pagination>
          <StartPage>1524</StartPage>
          <EndPage>1527</EndPage>
          <MedlinePgn>1524-1527</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/acn3.51403</ELocationID>
        <Abstract>
          <AbstractText>We present a female patient in her early twenties with global development delay, progressive ataxia, epilepsy, and myoclonus caused by a stop mutation in the SEMA6B gene. Truncating DNA variants located in the last exon of SEMA6B have recently been identified as a cause of autosomal dominant progressive myoclonus epilepsy. In many cases, myoclonus in the context of progressive myoclonic epilepsy is refractory to medical treatment. In the present case, treatment with zonisamide caused clinical improvement, particularly of positive and negative truncal myoclonus, considerably improving patient's gait and thus mobility.</AbstractText>
          <CopyrightInformation>© 2021 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Herzog</LastName>
            <ForeName>Rebecca</ForeName>
            <Initials>R</Initials>
            <Identifier Source="ORCID">0000-0002-5906-5947</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Systems Motor Science, University Lübeck, Lübeck, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University of Lübeck, Lübeck, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hellenbroich</LastName>
            <ForeName>Yorck</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Human Genetics, University of Lübeck, Lübeck, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brüggemann</LastName>
            <ForeName>Norbert</ForeName>
            <Initials>N</Initials>
            <Identifier Source="ORCID">0000-0001-5969-6899</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University of Lübeck, Lübeck, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Neurogenetics, University of Lübeck, Lübeck, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Brain, Behavior and Metabolism (CBBM), University of Lübeck, Lübeck, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lohmann</LastName>
            <ForeName>Katja</ForeName>
            <Initials>K</Initials>
            <Identifier Source="ORCID">0000-0002-5121-1460</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Neurogenetics, University of Lübeck, Lübeck, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Grimmel</LastName>
            <ForeName>Mona</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Human Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Haack</LastName>
            <ForeName>Tobias B</ForeName>
            <Initials>TB</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Human Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Centre for Rare Diseases, University of Tübingen, Tübingen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>von Spiczak</LastName>
            <ForeName>Sarah</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>DRK-Northern German Epilepsy Center, Schwentinental-Raisdorf, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Münchau</LastName>
            <ForeName>Alexander</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0002-3219-2284</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Systems Motor Science, University Lübeck, Lübeck, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Brain, Behavior and Metabolism (CBBM), University of Lübeck, Lübeck, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>06</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Ann Clin Transl Neurol</MedlineTA>
        <NlmUniqueID>101623278</NlmUniqueID>
        <ISSNLinking>2328-9503</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C504081">SEMA6B protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D039961">Semaphorins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>459384H98V</RegistryNumber>
          <NameOfSubstance UI="D000078305">Zonisamide</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020191" MajorTopicYN="N">Myoclonic Epilepsies, Progressive</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010375" MajorTopicYN="N">Pedigree</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D039961" MajorTopicYN="N">Semaphorins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000073359" MajorTopicYN="N">Whole Exome Sequencing</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000078305" MajorTopicYN="N">Zonisamide</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare that there are no conflicts of interest relevant to this work and that there are no additional disclosures to report.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>6</Day>
          <Hour>21</Hour>
          <Minute>29</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34092044</ArticleId>
        <ArticleId IdType="pmc">PMC8283161</ArticleId>
        <ArticleId IdType="doi">10.1002/acn3.51403</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Correa RG, Sasahara RM, Bengtson MH, et al. Human semaphorin 6B [(HSA)SEMA6B], a novel human class 6 semaphorin gene: alternative splicing and all‐trans‐retinoic acid‐dependent downregulation in glioblastoma cell lines. Genomics
2001;73:343–348.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11350127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hamanaka K, Imagawa E, Koshimizu E, et al. De novo truncating variants in the last exon of SEMA6B cause progressive myoclonic epilepsy. Am J Hum Genet
2020;106:549–558.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7118575</ArticleId>
            <ArticleId IdType="pubmed">32169168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Courage C, Oliver KL, Park EJ, et al. Progressive myoclonus epilepsies‐Residual unsolved cases have marked genetic heterogeneity including dolichol‐dependent protein glycosylation pathway genes. Am J Hum Genet
2021;108:722–738.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8059372</ArticleId>
            <ArticleId IdType="pubmed">33798445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Holmes GL. Drug treatment of progressive myoclonic epilepsy. Paediatr Drugs
2020;22:149–164.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7901803</ArticleId>
            <ArticleId IdType="pubmed">31939107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fritzen D, Kuechler A, Grimmel M, et al. De novo FBXO11 mutations are associated with intellectual disability and behavioural anomalies. Hum Genet
2018;137:401–411.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29796876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Henry TR, Leppik IE, Gumnit RJ, Jacobs M. Progressive myoclonus epilepsy treated with zonisamide. Neurology
1988;38:928–931.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3130586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
O'Rourke D, Flynn C, White M, et al. Potential efficacy of zonisamide in refractory juvenile myoclonic epilepsy: retrospective evidence from an Irish compassionate‐use case series. Ir Med J
2007;100:431–433.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17566478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Suzuki S, Kawakami K, Nishimura S, et al. Zonisamide blocks T‐type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res
1992;12:21–27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1326433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kyllerman M, Ben‐Menachem E. Zonisamide for progressive myoclonus epilepsy: long‐term observations in seven patients. Epilepsy Res
1998;29:109–114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9477142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Vossler DG, Conry JA, Murphy JV, Group Z‐PS
. Zonisamide for the treatment of myoclonic seizures in progressive myoclonic epilepsy: an open‐label study. Epileptic Disord.
2008;10:31–34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18367429</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
